Nilotinib-treated patients with chronic myeloid leukemia had a significantly higher increase in plasma insulin levels per unit of glucose compared to non-CML controls and imatinib-treated patients.
Cross-Sectional (n=42)
No
Does nilotinib therapy impair skeletal muscle glucose handling and insulin sensitivity compared to imatinib and healthy controls in non-diabetic patients with CML?
Nilotinib therapy in non-diabetic CML patients is associated with early signs of decreased skeletal muscle insulin sensitivity and compensatory hyperinsulinemia, highlighting the need for metabolic monitoring to mitigate cardiovascular risk.
Absolute Event Rate: 48% vs 37.2%
p-value: p=0.029
In this study, we have shown that non-diabetic patients with CML receiving nilotinib therapy show early signs of disturbed skeletal muscle glucose handling, which was not observed in imatinib-treated patients. These observations in nilotinib users may reflect decreased muscle insulin sensitivity, which could serve as a potential target to counteract glycemic dysregulation, and is of clinical importance since these patients have an increased cardiovascular disease risk.
Janssen et al. (Wed,) conducted a cross-sectional in Chronic myeloid leukemia (n=42). Nilotinib vs. Imatinib and non-CML controls was evaluated on Increase in plasma insulin levels per unit of glucose (pmol/L) (p=0.029). Nilotinib-treated patients with chronic myeloid leukemia had a significantly higher increase in plasma insulin levels per unit of glucose compared to non-CML controls and imatinib-treated patients.